Alnylam Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $588.2M | $820.0M |
| FY2022 | — | $-158.2M | $866.4M |
| FY2023 | — | $-220.6M | $812.7M |
| FY2024 | — | $67.1M | $966.4M |
| FY2025 | — | $789.2M | $1.66B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $588.2M | $820.0M |
| FY2022 | — | $-158.2M | $866.4M |
| FY2023 | — | $-220.6M | $812.7M |
| FY2024 | — | $67.1M | $966.4M |
| FY2025 | — | $789.2M | $1.66B |